KRAKOW, Poland, Feb. 27,
2020 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a
clinical stage biopharmaceutical company developing novel small
molecule therapies that address emerging targets in oncology, today
announced that data from its multiple oncology programs will be
presented at the American Association for Cancer Research (AACR)
Annual Meeting taking place April 24 to
April 29, 2020, in San Diego,
CA.
Data presented will include results from the small-molecule
STING agonists, dual A2A/A2B adenosine receptors antagonist
program, HPK1 inhibitors and SMARCA2 (BRM) degraders program.
Details of the poster presentations are as follows:
Title: In vivo and in vitro characterization of RVU330
best-in-class dual A2A/A2B adenosine receptor antagonist
Session Title: Immunomodulatory Agents and Interventions
2
Session Date and Time: Tuesday, April
28, 2020 1:30 PM - 5:00 PM
(PST)
Location: Section 46
Poster Board Number: 15
Permanent Abstract Number: 5555
Title: Development of selective small molecule STING
agonists suitable for systemic administration
Session
Title: Immunomodulatory Agents and Interventions 1
Session Date and Time: Tuesday, April
28, 2020, 9:00 AM - 12:30 PM
(PST)
Location: Poster Section 49
Poster Board Number: 27
Permanent Abstract Number: 4521A
Title: Development and characterization of small
molecule HPK1 inhibitors
Session Title: Small
Molecule Therapeutic Agents
Session Date and Time: Monday, April
27, 2020 9:00 AM - 12:30 PM
(PST)
Location: Poster Section 31
Poster Board Number: 14
Permanent Abstract Number: 1947
Title: Development of novel, selective SMARCA2 (BRM)
degraders for treatment of SMARCA4 (BRG1) mutated tumors
Session Category: Molecular and Cellular
Biology/Genetics
Session Title: Histone Modifications and Epigenomics
Session Date and Time: Tuesday, April
28, 2020 9:00 AM - 12:30 PM
(PST)
Location: Poster Section 9
Poster Board Number: 15
Permanent Abstract Number: 3656
Presentations will be held at the San
Diego Convention Center, Exhibit Halls A-F, in respective
Poster Sections. Additional information is available at on the AACR
conference website http://www.aacr.org.
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical stage biopharmaceutical company
developing novel small molecule therapies that address emerging
targets in oncology. Pipeline candidates make use of diverse
therapeutic mechanisms driven by emerging knowledge of cancer
biology, including small molecules directed at kinase, synthetic
lethality, immuno-oncology and cancer metabolism targets. SEL120 is
a selective CDK8 kinase inhibitor with potential for the treatment
of hematological malignancies and solid tumors currently in
clinical development for the treatment of acute myeloid leukemia
and myelodysplastic syndrome. SEL24/MEN1703 is a dual PIM/FLT3
kinase inhibitor licensed to the Menarini Group in clinical
development for the treatment of acute myeloid leukemia. For more
information, please see www.ryvu.com.
Contacts:
Natalia Baranowska
(corporate)
+48-784-069-418
natalia.baranowska@ryvu.com
Julia Balanova (investors)
+1-646-378-2936
jbalanova@troutgroup.com
View original
content:http://www.prnewswire.com/news-releases/ryvu-therapeutics-to-present-recent-data-from-multiple-oncology-programs-at-aacr-2020-annual-meeting-301012416.html
SOURCE Ryvu Therapeutics